We are live on ! Find out more
BXRX

Baudax Bio, Inc. Common Stock
BXRX

Delisted

BXRX was delisted on the 15th of November, 2023.

Back to rankings

12 hedge funds and large institutions have $152K invested in Baudax Bio, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more capital invested

Capital invested by funds: $127K → $152K (+$25K)

0% more funds holding

Funds holding: 12 → 12 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
12
Holders Change
–
Holders Change %
0%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Creative Planning
Creative Planning
Kansas
+$43K
2
Jane Street
Jane Street
New York
+$26.1K
3
UBS Group
UBS Group
Switzerland
+$9.22K
4
TRCT
Tower Research Capital (TRC)
New York
+$8.61K
5
Wells Fargo
Wells Fargo
California
+$39

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$55.8K
2
JP Morgan Chase
JP Morgan Chase
New York
-$3K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.79K

BXRX Hedge Fund Activity: Q2 2023 in Review

12 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q2 2023, worth a combined $152K — up 20% from $127K a quarter earlier.

Fund positioning in BXRX was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 0 trimmed.

The largest buyer was Creative Planning, opening a new position worth an estimated $43K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $55.8K sold.

  • 12 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $152K of Baudax Bio, Inc. Common Stock stock for Q2 2023, up 20% quarter-over-quarter.
  • 3 funds opened new Baudax Bio, Inc. Common Stock positions in Q2 2023 and 3 closed out, a net change of 0 holders.
  • The largest Baudax Bio, Inc. Common Stock buyer in Q2 2023 was Creative Planning, an estimated $43K added.
  • The largest Baudax Bio, Inc. Common Stock seller in Q2 2023 was Susquehanna International Group, an estimated $55.8K sold.

Based on aggregated 13F filings for Q2 2023.